YRC Worldwide Inc., through its subsidiaries, provides various transportation services primarily in North America. The company has market cap of $330.16 million. The Company’s YRC Freight segment offers various services to transport industrial, commercial, and retail goods; and provides specialized services, including guaranteed expedited services, time-specific deliveries, cross-border services, coast-to-coast air delivery, product returns, temperature-sensitive shipment protection, and government material shipments. It currently has negative earnings. It serves manufacturing, wholesale, retail, and government customers.
Analysts expect Reata Pharmaceuticals, Inc. (NASDAQ:RETA) to report $-0.58 EPS on March, 2.They anticipate $0.39 EPS change or 205.26% from last quarter’s $-0.19 EPS. After having $-0.50 EPS previously, Reata Pharmaceuticals, Inc.’s analysts see 16.00% EPS growth. The stock decreased 1.33% or $0.36 during the last trading session, reaching $26.73. About 192,352 shares traded. Reata Pharmaceuticals, Inc. (NASDAQ:RETA) has 0.00% since February 17, 2017 and is . It has underperformed by 16.70% the S&P500.
The stock decreased 0.71% or $0.07 during the last trading session, reaching $9.85. About 685,830 shares traded. YRC Worldwide Inc. (YRCW) has risen 5.68% since February 17, 2017 and is uptrending. It has underperformed by 11.02% the S&P500.
Millrace Asset Group Inc. holds 2.23% of its portfolio in YRC Worldwide Inc. for 172,000 shares. Northpointe Capital Llc owns 1.26 million shares or 1.86% of their US portfolio. Moreover, Falcon Point Capital Llc has 1.63% invested in the company for 831,242 shares. The New York-based Phoenix Investment Adviser Llc has invested 1.43% in the stock. 1492 Capital Management Llc, a Wisconsin-based fund reported 95,681 shares.